A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19.
Nakamura K, Fujimoto K, Hasegawa C, Aoki I, Yoshitsugu H, Ugai H, Yatsuzuka N, Tanaka Y, Furihata K, Maas BM, Wickremasingha PK, Duncan KE, Iwamoto M, Stoch SA, Uemura N.
Nakamura K, et al. Among authors: tanaka y.
Clin Transl Sci. 2022 Nov;15(11):2697-2708. doi: 10.1111/cts.13395. Epub 2022 Sep 23.
Clin Transl Sci. 2022.
PMID: 36053806
Free PMC article.
Clinical Trial.